Clinical trials: SARSCoV2 Convalescent Plasma
Covid19
Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development
Collection of SARS-COV-2 Secretions and Serum for Countermeasure Development (aka ClinSeqSer) is an observational study to understand natural history of SARS-COV-2 infections among special populations and characterise post-covid…
- Trial name
- NCT04956445
- Where
- 2 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Tulane University
Convalescent Plasma, COVID-19
Efficacy and Safety of COVID-19 Convalescent Plasma
Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
- Conditions
- Convalescent Plasma, COVID-19, SARS-CoV 2
- Trial name
- NCT04397523
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- North Macedonia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Institute for Transfusion Medicine of RNM
Healthy
Convalescent Plasma Donor Vaccine Study An Observational Antibody Level Study.
There is a need to understand antibody responses following SARS-COV-2 infection and subsequent vaccination.
- Trial name
- C-VELVET (NCT04954937)
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- NHS Blood and Transplant
SARS-CoV 2, COVID-19
Convalescent Plasma for Early Treatment of COVID-19
This is a double-blinded, randomized control trial to assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma as early treatment.
- Trial name
- NCT04390503
- Testing
- Convalescent Plasma (anti-SARS-CoV-2 plasma), Control (albumin 5%)
- Where
- Brazil
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- Andrew Eisenberger
Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection)
Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19
This project investigates individual treatments using convalescent severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2) plasma in SARS-CoV-2 infected patients at risk for disease progression.
- Trial name
- NCT04389944
- Testing
- convalescent plasma application to SARS-CoV-2 infected patients
- Where
- Switzerland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
COVID-19
Use of Multiple Doses of Convalescent Plasma in Mechanically Intubated Patients With COVID-19
This study will assess the feasibility and safety of administering multiple doses of convalescent plasma to Covid-19 positive patients admitted to the Intensive Care Unit (ICU) receiving mechanical ventilation.
- Trial name
- NCT05595538
- Testing
- Multiple doses of anti-SARS-CoV-2 Convalescent Plasma
- Where
- Panama
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hospital Regional Dr. Rafael Estévez
Coronavirus, Convalescence
Convalescent Plasma to Stem Coronavirus (CSSC-001)
Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28.
- Trial name
- CSSC-001 (NCT04323800)
- Testing
- Anti- SARS-CoV-2 Plasma, SARS-CoV-2 non-immune Plasma
- Where
- 25 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Coronavirus Disease 2019 (COVID-19)
Collection of Anti-SARS-CoV-2 Immune Plasma
Background: The human disease caused by SARS-CoV-2 is called COVID-19. In most cases, COVID-19 is a mild to moderate respiratory illness. But it can also be more severe and even lead to death.
- Trial name
- NIAID (NCT04344977)
- Where
- 3 sites in United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)